Xencor Inc

-0.86 (-3.07%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.63B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$25.04 Million
Adjusted EPS-$0.68
See more estimates
10-Day MA$28.00
50-Day MA$31.68
200-Day MA$28.87
See more pivots

Xencor Inc Stock, NASDAQ:XNCR

111 West Lemon Avenue, 2nd floor, Monrovia, California 91016
United States of America
Phone: +1.626.305.5900
Number of Employees: 281


Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.